A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
Public ClinicalTrials.gov record NCT06282159. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
Study identification
- NCT ID
- NCT06282159
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Dianthus Therapeutics
- Industry
- Enrollment
- 65 participants
Conditions and interventions
Conditions
Interventions
- Claseprubart Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 22, 2024
- Primary completion
- Jul 27, 2025
- Completion
- Sep 30, 2028
- Last update posted
- Jun 7, 2026
2024 – 2028
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Study Site | Phoenix | Arizona | 85028 | — |
| Clinical Study Site | Irvine | California | 92868 | — |
| Clinical Study Site | Stamford | Connecticut | 06905 | — |
| Clinical Study Site | Boca Raton | Florida | 33487 | — |
| Clinical Study Site | Bradenton | Florida | 34205 | — |
| Clinical Study Site | Maitland | Florida | 32751 | — |
| Clincal Study Site | Tampa | Florida | 33620 | — |
| Clinical Study Site | O'Fallon | Illinois | 62269 | — |
| Clinical Study Site | Kansas City | Kansas | 66103 | — |
| Clinical Study Site | Lexington | Kentucky | 40503 | — |
| Clinical Study Site | Boston | Massachusetts | 02215 | — |
| Clinical Study Site | East Lansing | Michigan | 48824 | — |
| Clinical Study Site | Columbia | Missouri | 65212 | — |
| Clinical Study Site | Cincinnati | Ohio | 45219 | — |
| Clinical Study Site | Columbus | Ohio | 43221 | — |
| Clinical Study Site | Dallas | Texas | 75206 | — |
| Clinical Study Site | Dallas | Texas | 75243 | — |
| Clinical Study Site #2 | Houston | Texas | 77030 | — |
| Clinical Study Site | Houston | Texas | 77030 | — |
| Clinical Study Site | Lubbock | Texas | 79414 | — |
| Clinical Study Site | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06282159, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 7, 2026 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06282159 live on ClinicalTrials.gov.